Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 3, 2012, Pages 340-349

  Van Norden, Anouk G W ^a   Van Dijk, Ewoud J ^a   De Laat, Karlijn F ^a   Scheltens, Philip ^b   OldeRikkert, Marcel G M ^a   De Leeuw, F E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Amyloid; Dementia; Imaging; Vascular

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BAPINEUZUMAB; CALCIUM ANTAGONIST; CHLORTALIDONE; CYCLOOXYGENASE 2 INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; PRESENILIN; TARENFLURBIL; TAU PROTEIN;

ALLELE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN SIZE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; HUMAN; MEDIAL TEMPORAL LOBE ATROPHY; MEMORY DISORDER; MENINGOENCEPHALITIS; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROVASCULAR DYSFUNCTION; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENILE PLAQUE; STROKE PATIENT; SYSTOLIC HYPERTENSION; VASCULAR DISEASE; WHITE MATTER LESION;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; DISEASE PROGRESSION; HUMANS; PEPTIDES;

EID: 84856028442     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.07.003     Document Type: Article

References (138)

1. Qiu C., De Ronchi D., Fratiglioni L. The epidemiology of the dementias: an update. Curr. Opin. Psychiatry 2007, 20:380-385.
2. Alzheimer A. Uber einen eigenartige erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 1907, 64:146-148.
3. De Groot J.C., De Leeuw F.E., Oudkerk M., Van Gijn J., Hofman A., Jolles J., Breteler M.M. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann. Neurol. 2002, 52:335-341.
4. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstaal P.J., Breteler M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 2003, 348:1215-1222.
5. Verdelho A., Madureira S., Moleiro C., Ferro J.M., Santos C.O., Erkinjuntti T., Pantoni L., Fazekas F., Visser M., Waldemar G., Wallin A., Hennerici M., Inzitari D. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010, 75:160-167.
6. Au R., Massaro J.M., Wolf P.A., Young M.E., Beiser A., Seshadri S., D'Agostino R.B., DeCarli C. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch. Neurol. 2006, 63:246-250.
7. Hajjar I., Quach L., Yang F., Chaves P.H., Newman A.B., Mukamal K., Longstreth W., Inzitari M., Lipsitz L.A. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation 2011, 123:858-865.
8. Roth M., Tomlinson B.E., Blessed G. Correlation between scores for dementia and counts of 'senile plaques' in cerebral grey matter of elderly subjects. Nature 1966, 209:109-110.
9. Tomlinson B.E., Blessed G., Roth M. Observations on the brains of demented old people. J. Neurol. Sci. 1970, 11:205-242.
10. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
11. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122:1131-1135.
12. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:4245-4249.
13. Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D., Lieberburg I., van Duinen S.G., Bots G.T., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage. Dutch type, Science 1990, 248:1124-1126.
14. Van Broeckhoven C., Haan J., Bakker E., Hardy J.A., Van Hul W., Wehnert A., Vegter-Van der Vlis M., Roos R.A. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis. Science 1990, 248:1120-1122.
15. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2:864-870.
16. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992, 360:672-674.
17. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
18. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
19. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359:325-327.
20. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258:126-129.
21. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
22. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
23. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
24. Schellenberg G.D., Bird T.D., Wijsman E.M., Orr H.T., Anderson L., Nemens E., White J.A., Bonnycastle L., Weber J.L., Alonso M.E., et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992, 258:668-671.
25. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
26. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
27. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
28. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
29. Roher A.E., Chaney M.O., Kuo Y.M., Webster S.D., Stine W.B., Haverkamp L.J., Woods A.S., Cotter R.J., Tuohy J.M., Krafft G.A., Bonnell B.S., Emmerling M.R. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 1996, 271:20631-20635.
30. Wahlund L.O., Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci. Lett. 2003, 339:99-102.
31. Blennow K., Vanmechelen E., Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 2001, 24:87-97.
32. Visser P.J., Verhey F., Knol D.L., Scheltens P., Wahlund L.O., Freund-Levi Y., Tsolaki M., Minthon L., Wallin A.K., Hampel H., Burger K., Pirttila T., Soininen H., Rikkert M.O., Verbeek M.M., Spiru L., Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009, 8:619-627.
33. Samgard K., Zetterberg H., Blennow K., Hansson O., Minthon L., Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int. J. Geriatr. Psychiatry 2009, 25:403-410.
34. Ziolko S.K., Weissfeld L.A., Klunk W.E., Mathis C.A., Hoge J.A., Lopresti B.J., DeKosky S.T., Price J.C. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006, 33:94-102.
35. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
36. Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., Wall A., Ringheim A., Langstrom B., Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
37. Vallabhajosula S. Positron emission tomography radiopharmaceuticals for imaging brain beta-amyloid. Semin. Nucl. Med. 2011, 41:283-299.
38. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., Pontecorvo M.J., Hefti F., Carpenter A.P., Flitter M.L., Krautkramer M.J., Kung H.F., Coleman R.E., Doraiswamy P.M., Fleisher A.S., Sabbagh M.N., Sadowsky C.H., Reiman E.P., Zehntner S.P., Skovronsky D.M. Use of florbetapir-PET for imaging of beta-amyloid pathology. JAMA 2011, 305:275-283.
39. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
40. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5:452-457.
41. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
42. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
43. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
44. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., Mulnard R., Barakos J., Gregg K.M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.
45. Green R.C., Schneider L.S., Amato D.A., Beelen A.P., Wilcock G., Swabb E.A., Zavitz K.H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302:2557-2564.
46. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., Goodman S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004, 23:159-169.
47. de Jong D., Jansen R., Hoefnagels W., Jellesma-Eggenkamp M., Verbeek M., Borm G., Kremer B. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 2008, 3:e1475.
48. Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., Norman B.A., Baranak C.C. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004, 62:66-71.
49. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.
50. Bouwman F.H., van der Flier W.M., Schoonenboom N.S., van Elk E.J., Kok A., Rijmen F., Blankenstein M.A., Scheltens P. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007, 69:1006-1011.
51. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
52. Cummings B.J., Cotman C.W. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 1995, 346:1524-1528.
53. Davis D.G., Schmitt F.A., Wekstein D.R., Markesbery W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 1999, 58:376-388.
54. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
55. Morris J.C., Price A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 2001, 17:101-118.
56. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001, 357:169-175.
57. Morgan D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem. Res. 2003, 28:1029-1034.
58. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3228-3233.
59. Price J.L., McKeel D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., Smith C.D., Davis D.G., Schmitt F.A., Markesbery W.R., Kaye J., Kurlan R., Hulette C., Kurland B.F., Higdon R., Kukull W., Morris J.C. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30:1026-1036.
60. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
61. Walsh D.M., Klyubin I., Shankar G.M., Townsend M., Fadeeva J.V., Betts V., Podlisny M.B., Cleary J.P., Ashe K.H., Rowan M.J., Selkoe D.J. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 2005, 33:1087-1090.
62. Robakis N.K. Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives. Neurobiol. Aging 2011, 32:371-379.
63. Shen J., Kelleher R.J. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:403-409.
64. Trojanowski J.Q., Lee V.M. Rous-Whipple award lecture. The Alzheimer's brain: finding out what's broken tells us how to fix it. Am. J. Pathol. 2005, 167:1183-1188.
65. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006, 20:112-117.
66. Hachinski V.C., Potter P., Merskey H. Leuko-araiosis. Arch. Neurol. 1987, 44:21-23.
67. Steingart A., Hachinski V.C., Lau C., Fox A.J., Diaz F., Cape R., Lee D., Inzitari D., Merskey H. Cognitive and neurologic findings in subjects with diffuse white matter lucencies on computed tomographic scan (leuko-araiosis). Arch. Neurol. 1987, 44:32-35.
68. Steingart A., Hachinski V.C., Lau C., Fox A.J., Fox H., Lee D., Inzitari D., Merskey H. Cognitive and neurologic findings in demented patients with diffuse white matter lucencies on computed tomographic scan (leuko-araiosis). Arch. Neurol. 1987, 44:36-39.
69. de Leeuw F.E., de Groot J.C., Oudkerk M., Witteman J.C., Hofman A., van Gijn J., Breteler M.M. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002, 125:765-772.
70. de Leeuw F.E., de Groot J.C., Oudkerk M., Kors J.A., Hofman A., van Gijn J., Breteler M.M. Atrial fibrillation and the risk of cerebral white matter lesions. Neurology 2000, 54:1795-1801.
71. de Leeuw F.E., de Groot J.C., Bots M.L., Witteman J.C., Oudkerk M., Hofman A., van Gijn J., Breteler M.M. Carotid atherosclerosis and cerebral white matter lesions in a population based magnetic resonance imaging study. J. Neurol. 2000, 247:291-296.
72. Ott A., Breteler M.M., de Bruyne M.C., van Harskamp F., Grobbee D.E., Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997, 28:316-321.
73. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
74. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997, 349:151-154.
75. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002, 346:476-483.
76. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001, 322:1447-1451.
77. Sparks D.L., Hunsaker J.C., Scheff S.W., Kryscio R.J., Henson J.L., Markesbery W.R. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 1990, 11:601-607.
78. de la Torre J.C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004, 3:184-190.
79. Forette F., Seux M.L., Staessen J.A., Thijs L., Birkenhager W.H., Babarskiene M.R., Babeanu S., Bossini A., Gil-Extremera B., Girerd X., Laks T., Lilov E., Moisseyev V., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
80. Forette F., Seux M.L., Staessen J.A., Thijs L., Babarskiene M.R., Babeanu S., Bossini A., Fagard R., Gil-Extremera B., Laks T., Kobalava Z., Sarti C., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Birkenhager W.H. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 2002, 162:2046-2052.
81. Trompet S., Westendorp R.G., Kamper A.M., de Craen A.J. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol. Aging 2008, 29:306-308.
82. Tzourio C., Anderson C., Chapman N., Woodward M., Neal B., MacMahon S., Chalmers J. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 2003, 163:1069-1075.
83. Shlyakhto E. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from >10,000 patients and review of the literature. Curr. Med. Res. Opin. 2007, 23(Suppl 5):S13-S18.
84. Applegate W.B., Pressel S., Wittes J., Luhr J., Shekelle R.B., Camel G.H., Greenlick M.R., Hadley E., Moye L., Perry H.M., et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch. Intern. Med. 1994, 154:2154-2160.
85. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., Westendorp R.G. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
86. Peters R., Beckett N., Forette F., Tuomilehto J., Clarke R., Ritchie C., Waldman A., Walton I., Poulter R., Ma S., Comsa M., Burch L., Fletcher A., Bulpitt C. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008, 7:683-689.
87. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 2003, 21:875-886.
88. McGuinness B., Todd S., Passmore P., Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev. 2009, CD004034.
89. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, text revision, Washington DC. 4th edition.
90. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
91. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
92. Jellinger K.A. Morphologic diagnosis of "vascular dementia" - a critical update. J. Neurol. Sci. 2008, 270:1-12.
93. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The nun study. JAMA 1997, 277:813-817.
94. Launer L.J., Petrovitch H., Ross G.W., Markesbery W., White L.R. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol. Aging 2008, 29:1587-1590.
95. van der Flier W.M., Barkhof F., Scheltens P. Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. Ann. N.Y. Acad. Sci. 2007, 1097:215-224.
96. Brickman A.M., Honig L.S., Scarmeas N., Tatarina O., Sanders L., Albert M.S., Branst J., Blacker D., Stern Y. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch. Neurol. 2008, 65:1202-1208.
97. Li L., Zhang X., Yang D., Luo G., Chen S., Le W. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol. Aging 2009, 30:1091-1098.
98. Zhiyou C., Yong Y., Shanquan S., Jun Z., Liangguo H., Ling Y., Jieying L. Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem. Res. 2009, 34:1226-1235.
99. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48:913-922.
100. Lewis H., Beher D., Cookson N., Oakley A., Piggott M., Morris C.M., Jaros E., Perry R., Ince P., Kenny R.A., Ballard C.G., Shearman M.S., Kalaria R.N. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol. Appl. Neurobiol. 2006, 32:103-118.
101. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996, 380:168-171.
102. Kalaria R.N. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc. Dis. 2002, 13(Suppl 2):48-52.
103. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010, 120:287-296.
104. Kadir A., Marutle A., Gonzalez D., Scholl M., Almkvist O., Mousavi M., Mustafiz T., Darreh-Shori T., Nennesmo I., Nordberg A. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011, 134:301-317.
105. Braak H., Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 1996, 165:3-12.
106. Korf E.S., Wahlund L.O., Visser P.J., Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004, 63:94-100.
107. de Leeuw F.E., Korf E., Barkhof F., Scheltens P. White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. Stroke 2006, 37:2248-2252.
108. de Leeuw F.E., Barkhof F., Scheltens P. White matter lesions and hippocampal atrophy in Alzheimer's disease. Neurology 2004, 62:310-312.
109. den Heijer T., Vermeer S.E., van Dijk E.J., Prins N.D., Koudstaal P.J., Hofman A., Breteler M.M. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003, 46:1604-1610.
110. den Heijer T., Launer L.J., Prins N.D., van Dijk E.J., Vermeer S.E., Hofman A., Koudstaal P.J., Breteler M.M. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005, 64:263-267.
111. Korf E.S., Scheltens P., Barkhof F., de Leeuw F.E. Blood pressure, white matter lesions and medial temporal lobe atrophy: closing the gap between vascular pathology and Alzheimer's disease?. Dement. Geriatr. Cogn. Disord. 2005, 20:331-337.
112. Snaphaan L., Rijpkema M., van Uden I., Fernandez G., de Leeuw F.E. Reduced medial temporal lobe functionality in stroke patients: a functional magnetic resonance imaging study. Brain 2009, 132:1882-1888.
113. Kalaria R.N. Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. Nat. Rev. Neurol. 2009, 5:305-306.
114. Helzner E.P., Luchsinger J.A., Scarmeas N., Cosentino S., Brickman A.M., Glymour M.M., Stern Y. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch. Neurol. 2009, 66:343-348.
115. Honig L.S., Kukull W., Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005, 64:494-500.
116. Beach T.G., Wilson J.R., Sue L.I., Newell A., Poston M., Cisneros R., Pandya Y., Esh C., Connor D.J., Sabbagh M., Walker D.G., Roher A.E. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 2007, 113:13-21.
117. Deschaintre Y., Richard F., Leys D., Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009, 73:674-680.
118. Greenberg S.M., Vernooij M.W., Cordonnier C., Viswanathan A., Al-Shahi Salman R., Warach S., Launer L.J., Van Buchem M.A., Breteler M.M. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009, 8:165-174.
119. Vinters H.V. Cerebral amyloid angiopathy. A critical review. Stroke 1987, 18:311-324.
120. Attems J., Lintner F., Jellinger K.A. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol. 2004, 107:283-291.
121. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994, 17:525-530.
122. Lahoz C., Schaefer E.J., Cupples L.A., Wilson P.W., Levy D., Osgood D., Parpos S., Pedro-Botet J., Daly J.A., Ordovas J.M. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001, 154:529-537.
123. Kokubo Y., Chowdhury A.H., Date C., Yokoyama T., Sobue H., Tanaka H. Age-dependent association of apolipoprotein E genotypes with stroke subtypes in a Japanese rural population. Stroke 2000, 31:1299-1306.
124. van Dijk E.J., Prins N.D., Vermeer S.E., Hofman A., van Duijn C.M., Koudstaal P.J., Breteler M.M. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann. Neurol. 2004, 55:570-575.
125. de Leeuw F.E., Richard F., de Groot J.C., van Duijn C.M., Hofman A., Van Gijn J., Breteler M.M. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004, 35:1057-1060.
126. Hirono N., Yasuda M., Tanimukai S., Kitagaki H., Mori E. Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. Stroke 2000, 31:1263-1268.
127. Kuller L.H., Shemanski L., Manolio T., Haan M., Fried L., Bryan N., Burke G.L., Tracy R., Bhadelia R. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 1998, 29:388-398.
128. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bales K., Ashe K.H., Irizarry M.C., Hyman B.T. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 2000, 47:739-747.
129. Greenberg S.M., Rebeck G.W., Vonsattel J.P., Gomez-Isla T., Hyman B.T. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 1995, 38:254-259.
130. Vidal R., Calero M., Piccardo P., Farlow M.R., Unverzagt F.W., Mendez E., Jimenez-Huete A., Beavis R., Gallo G., Gomez-Tortosa E., Ghiso J., Hyman B.T., Frangione B., Ghetti B. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele. Acta Neuropathol. 2000, 100:1-12.
131. Yip A.G., McKee A.C., Green R.C., Wells J., Young H., Cupples L.A., Farrer L.A. APOE, vascular pathology, and the AD brain. Neurology 2005, 65:259-265.
132. Cordonnier C., van der Flier W.M. Brain microbleeds and Alzheimer's disease: innocent observation or key player?. Brain 2011, 134:335-344.
133. van Dijk E.J., Prins N.D., Hofman A., van Duijn C.M., Koudstaal P.J., Breteler M.M. Plasma beta amyloid and impaired CO2-induced cerebral vasomotor reactivity. Neurobiol. Aging 2007, 28:707-712.
134. Kriete A., Sokhansanj B.A., Coppock D.L., West G.B. Systems approaches to the networks of aging. Ageing Res. Rev. 2006, 5:434-448.
135. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
136. Matsusue E., Sugihara S., Fujii S., Ohama E., Kinoshita T., Ogawa T. White matter changes in elderly people: MR-pathologic correlations. Magn. Reson. Med. Sci. 2006, 5:99-104.
137. Basser P.J., Mattiello J., LeBihan D. Estimation of the effective self-diffusion tensor from the NMR spin echo. J. Magn. Reson. 1994, 103:247-254.
138. Brickman A.M., Muraskin J., Zimmerman M.E. Structural neuroimaging in Alzheimer's disease: do white matter hyperintensities matter?. Dialogues Clin. Neurosci. 2009, 11:181-190.